Abbott Laboratories raised its 2026 profit guidance after a stronger-than-expected second quarter driven by improved performance across most of its business lines. The medical device and healthcare company cited broad-based growth across its established pharmaceuticals, diagnostics, nutrition, and medical devices segments as the catalyst for the upward revision.

Management indicated that the improved outlook reflects sustained momentum in key growth platforms, including its FreeStyle Libre glucose monitoring system and structural heart therapies. The company now expects adjusted earnings per share for 2026 to exceed previous estimates, signaling confidence in its diversified portfolio's resilience amid macroeconomic headwinds.

Quarterly results showed organic sales growth accelerating across geographies, with particular strength in international markets. The diagnostics division benefited from normalized testing demand, while the nutrition segment continued to gain share in pediatric and adult categories. Medical devices posted double-digit growth in several franchises, offsetting lingering pressure in rhythm management.

Analysts viewed the guidance increase as a positive signal of execution consistency, noting Abbott's ability to compound growth across multiple vectors simultaneously.